MaxCyteMXCT
Fair Value
US$5
Share price11 Jan
US$1.2874.4% undervalued intrinsic discount
1Y-43.11%
7D4.06%
Gene Editing Royalties And Slow Adoption Will Pressure Results Yet Support Long Term Upside
AN
Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
11 Jan 26
Views
15
Not Invested